Navigation Links
Gene may hold key to future cancer hope

Scientists may have discovered a new way of killing tumours in what they hope could one day lead to alternative forms of cancer treatments.

The University of Manchester research has identified a key gene that appears to play a critical role in the normal process of cell division.

Cells divide creating new cells as part of the bodys natural growth, renewal and healing processes but cancer results when cells divide in an uncontrolled way.

What the Manchester team has discovered is that a protein in our cells called Bub 1 is essential for normal cell division to take place; if the gene that generates Bub 1 is switched off then the cells are unable to divide successfully.

Bub 1 is an enzyme that controls several processes required for cell division to occur, said Dr Stephen Taylor, who led the research in the Faculty of Life Sciences.

We have shown that mouse embryos lacking the Bub 1 gene are unable to develop. Older cell types also failed to divide when the gene is switched off, while male mice lacking Bub 1 became infertile as their sperm cells died.

In fact, deactivating Bub 1 had such a profound effect on cell division at all stages of a cells life - known as the cell cycle - that the team is hopeful it will have a similar effect on cancer cells.

Before cells can divide they have to duplicate and then distribute their genetic material so that the two daughter cells receive all the genetic information for further growth and development, said Dr Taylor, whose work is funded by the charity Cancer Research UK.

The distribution phase has to be done with a high degree of accuracy - just one chromosome segregated incorrectly, for instance, leads to Downs syndrome - so the cell has a surveillance mechanism which acts as a brake to delay chromosome segregation until accuracy has been guaranteed.

An important part of this intricate surveillance system is Bub 1. The team found that when the gene is switched off the surveillance mechanism fails and accuracy is lost, resulting in cell death.

Now that scientists understand the precise role of Bub 1 in normal cell division, as well as what goes wrong when the gene is missing, they plan to test their theory on cancer cells.

Unlike some other genes that become mutated in cancer cells, the Bub 1 gene appears normal indicating that it behaves in exactly the same way in cancer cells as it does in healthy cells.

If this is the case, then we can be confident that switching it off will stop cancer cells proliferating too. And while our normal cells dont divide that often, cancer cells divide more frequently, so hopefully by targeting Bub1 we will selectively kill cancer cells.

Equally exciting, says Dr Taylor, is the fact that drugs are already being developed that are able to block the actions of Bub 1-type enzymes, known as protein kinases; such kinase blockers or inhibitors are already providing a whole new approach to tackling cancer and Bub1 inhibitors may be another weapon in the oncologist's arsenal.

The research, which began in 1999, is published in the journal Developmental Cell on Tuesday, October 9.

Contact: Aeron Haworth
University of Manchester

Related biology news :

1. HIV vaccine trial breaks ground for future research
2. Future diabetes drugs may target new protein interaction
3. Prozac for future Plants on Mars
4. Purdues gold nanorods brighten future for medical imaging
5. Plants reveal a secret and bring researchers nearer a cleaner future
6. Report focuses on challenges to unlocking future promise of vaccines
7. Researchers make long DNA wires for future medical and electronic devices
8. New U. of Colorado at Boulder flu chip may help combat future epidemics, pandemics
9. Understanding the oceans microbes is key to the Earths future
10. Tastier tomatoes in the future?
11. Stable polymer nanotubes may have a biotech future
Post Your Comments:
(Date:11/2/2015)... , Nov. 2, 2015  SRI International has ... to provide preclinical development services to the National Cancer ... SRI will provide scientific expertise, modern testing and support ... of preclinical pharmacology and toxicology studies to evaluate potential ... --> The PREVENT Cancer Drug Development Program is ...
(Date:10/29/2015)... LA JOLLA, Calif. , Oct. 29, 2015 /PRNewswire-USNewswire/ ... released a new report titled, "DNA Synthesis and Biosecurity: ... how well the Department of Health and Human Services ... was issued in 2010. --> ... advances, but it also has the potential to pose ...
(Date:10/29/2015)... Mich. , Oct. 29, 2015  Rubicon ... Genomics for U.S. distribution of its DNA library ... kit and Rubicon,s new ThruPLEX Plasma-seq kit. ThruPLEX ... enable the preparation of NGS libraries for liquid ... for diagnostic and prognostic applications in cancer and ...
Breaking Biology News(10 mins):
(Date:11/30/2015)... (PRWEB) , ... November 30, 2015 , ... Global Stem Cells Group announced ... clinics in the cities of Arica and Iquique in northern Chile. The facilities are part ... offer the most advanced protocols and techniques in stem cell medicine to patients from around ...
(Date:11/30/2015)... /PRNewswire/ - BioAmber Inc. (NYSE: BIOA ), a leader in ... Business Act on Climate Pledge, alongside more than 140 companies ... Obama Administration to demonstrate an ongoing commitment to climate action ... COP21 Paris climate negotiations. ... Canada . --> BioAmber uses biotechnology to ...
(Date:11/30/2015)...  Culprits beware, a University at Albany research ... is taking crime scene fingerprint identification to a ... -->   --> Photo ... --> Halámek and his team ... concept for identifying whether a culprit is male ...
(Date:11/30/2015)... Nov. 30, 2015 /PRNewswire/ - Zenith Epigenetics Corp. ("Zenith" or ... Norman C.W. Wong to its Board of Directors to ... Zenith with a wealth of experience as co-founder of Resverlogix, ... --> --> Dr. Wong ... board of directors. Zenith,s long standing expertise in epigenetics and ...
Breaking Biology Technology: